Ligand Pharmaceuticals

108.42
3.60 (3.43%)
At close: Apr 02, 2025, 3:59 PM
108.73
0.29%
After-hours: Apr 02, 2025, 04:20 PM EDT

Ligand Pharmaceuticals Statistics

Share Statistics

Ligand Pharmaceuticals has 19.26M shares outstanding. The number of shares has increased by 7.19% in one year.

Shares Outstanding 19.26M
Shares Change (YoY) 7.19%
Shares Change (QoQ) 1.91%
Owned by Institutions (%) 98.92%
Shares Floating 18.78M
Failed to Deliver (FTD) Shares 49
FTD / Avg. Volume 0.05%

Short Selling Information

The latest short interest is 911.39K, so 4.82% of the outstanding shares have been sold short.

Short Interest 911.39K
Short % of Shares Out 4.82%
Short % of Float 4.93%
Short Ratio (days to cover) 7.07

Valuation Ratios

The PE ratio is -486.05 and the forward PE ratio is 19.25. Ligand Pharmaceuticals's PEG ratio is 4.53.

PE Ratio -486.05
Forward PE 19.25
PS Ratio 11.73
Forward PS 5.7
PB Ratio 2.36
P/FCF Ratio 20.58
PEG Ratio 4.53
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Ligand Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 8.93, with a Debt / Equity ratio of 0.01.

Current Ratio 8.93
Quick Ratio 8.55
Debt / Equity 0.01
Debt / EBITDA 0.17
Debt / FCF 0.07
Interest Coverage -7.44

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $2.46M
Profits Per Employee $-59.29K
Employee Count 68
Asset Turnover 0.18
Inventory Turnover 0.78

Taxes

Income Tax -6.55M
Effective Tax Rate -260.13%

Stock Price Statistics

The stock price has increased by 42.79% in the last 52 weeks. The beta is 1.03, so Ligand Pharmaceuticals's price volatility has been higher than the market average.

Beta 1.03
52-Week Price Change 42.79%
50-Day Moving Average 113.76
200-Day Moving Average 107.26
Relative Strength Index (RSI) 40.56
Average Volume (20 Days) 107.92K

Income Statement

In the last 12 months, Ligand Pharmaceuticals had revenue of 167.13M and earned -4.03M in profits. Earnings per share was -0.22.

Revenue 167.13M
Gross Profit 156.06M
Operating Income -22.61M
Net Income -4.03M
EBITDA 40.79M
EBIT 5.55M
Earnings Per Share (EPS) -0.22
Full Income Statement

Balance Sheet

The company has 72.31M in cash and 7.11M in debt, giving a net cash position of 65.2M.

Cash & Cash Equivalents 72.31M
Total Debt 7.11M
Net Cash 65.2M
Retained Earnings 498.98M
Total Assets 941.77M
Working Capital 294.45M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 97.05M and capital expenditures -1.82M, giving a free cash flow of 95.23M.

Operating Cash Flow 97.05M
Capital Expenditures -1.82M
Free Cash Flow 95.23M
FCF Per Share 5.21
Full Cash Flow Statement

Margins

Gross margin is 93.37%, with operating and profit margins of -13.53% and -2.41%.

Gross Margin 93.37%
Operating Margin -13.53%
Pretax Margin 1.51%
Profit Margin -2.41%
EBITDA Margin 24.41%
EBIT Margin -13.53%
FCF Margin 56.98%

Dividends & Yields

LGND does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for LGND is $141.5, which is 35.4% higher than the current price. The consensus rating is "Buy".

Price Target $141.5
Price Target Difference 35.4%
Analyst Consensus Buy
Analyst Count 6
Stock Forecasts

Stock Splits

The last stock split was on Nov 2, 2022. It was a forward split with a ratio of 1603:1000.

Last Split Date Nov 2, 2022
Split Type forward
Split Ratio 1603:1000

Scores

Altman Z-Score 11.09
Piotroski F-Score 3